☰

Stefanie R. Mullins, Ph.D. - Publications

Affiliations: 
2005 Wayne State University, Detroit, MI, United States 
Area:
Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kaistha BP, Kar G, Dannhorn A, Watkins A, Opoku-Ansah G, Ilieva K, Mullins S, Anderton J, Galvani E, Garcon F, Lapointe JM, Brown L, Hair J, Slidel T, Luheshi N, et al. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models. Cancer Biology & Therapy. 25: 2296048. PMID 38206570 DOI: 10.1080/15384047.2023.2296048  0.319
2020 Zanker DJ, Spurling AJ, Brockwell NK, Owen KL, Zakhour JM, Robinson T, Duivenvoorden HM, Hertzog PJ, Mullins SR, Wilkinson RW, Parker BS. Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clinical & Translational Immunology. 9: e1177. PMID 33005415 DOI: 10.1002/cti2.1177  0.313
2019 Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Journal For Immunotherapy of Cancer. 7: 244. PMID 31511088 DOI: 10.1186/S40425-019-0724-8  0.458
2018 Mullins SR, Vasilakos J, Deschler K, Grigsby I, Ren S, Elder MJ, Dovedi SJ, Leishman AJ, Ryan P, Cooper Z, Elvecrog J, Herbst R, Kumar R, Tomai M, Wilkinson RW. Abstract 711: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies Cancer Research. 78: 711-711. DOI: 10.1158/1538-7445.Am2018-711  0.429
2017 Xie B, Tomaszewski MR, Neves A, Ros S, Hu DE, McGuire S, Mullins SR, Tice DA, Sainson RCA, Bohndiek SE, Wilkinson RW, Brindle KM. Optoacoustic detection of early therapy-induced tumor cell death using a targeted imaging agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28821560 DOI: 10.1158/1078-0432.Ccr-17-1029  0.491
2017 Poon E, Mullins S, Watkins A, Williams GS, Koopmann JO, Di Genova G, Cumberbatch M, Veldman-Jones M, Grosskurth SE, Sah V, Schuller A, Reimer C, Dovedi SJ, Smith PD, Stewart R, et al. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. Journal For Immunotherapy of Cancer. 5: 63. PMID 28807001 DOI: 10.1186/S40425-017-0268-8  0.431
2017 Leyland R, Watkins A, Mulgrew K, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey KA, Young L, et al. A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28069723 DOI: 10.1158/1078-0432.Ccr-16-2000  0.311
2017 Mullins SR, Vogel K, Vasilakos J, Grigsby I, Dovedi S, Patricia R, Cooper Z, Herbst R, Kumar R, Tomai M, Wilkinson RW. Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors Cancer Research. 77: 4697-4697. DOI: 10.1158/1538-7445.Am2017-4697  0.517
2017 Xie B, Tomaszewski M, Neves AA, Mullins SR, Tice D, Sainson R, Bohndiek S, Wilkinson RW, Brindle KM. Abstract 2866: Volumetric optoacoustic imaging of tumor cell death using a targeted imaging agent Cancer Research. 77: 2866-2866. DOI: 10.1158/1538-7445.Am2017-2866  0.443
2016 Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunology Research. PMID 27923825 DOI: 10.1158/2326-6066.Cir-16-0114  0.441
2016 Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. PMID 26918344 DOI: 10.18632/Oncotarget.7610  0.32
2016 Xie B, Neves A, Mullins SR, Tice D, Carroll D, Wilkinson RW, Brindle KM. Abstract 4203: Non-invasive imaging of tumor cell death induced by a TRAILR2 agonist Cancer Research. 76: 4203-4203. DOI: 10.1158/1538-7445.Am2016-4203  0.441
2016 Mullins S, Grigsby I, Harrison LI, Ren S, Soukharev S, Young L, Elvecrog JM, Wilkinson RW, Tomai MA, Herbst R, Vasilakos JP, Leishman AJ. Abstract 1475: Local immune activation resulting in tumor growth inhibition with MEDI9197 - an intratumorally administered TLR7/8 agonist Cancer Research. 76: 1475-1475. DOI: 10.1158/1538-7445.Am2016-1475  0.485
2015 Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, et al. Identification and Pre-clinical Characterization of MEDI4736, an Antagonistic anti-PD-L1 Monoclonal Antibody. Cancer Immunology Research. PMID 25943534 DOI: 10.1158/2326-6066.Cir-14-0191  0.381
2015 Mullins SR, Poon E, Watkins A, Smith PD, Leishman A, Stewart R, Wilkinson R. Abstract 270: Preclinical assessment of combination therapy with selumetinib and CTLA-4 for cancer Cancer Research. 75: 270-270. DOI: 10.1158/1538-7445.Am2015-270  0.509
2014 Stewart R, Poon E, Mullins S, Watkins A, Smith PD, Wilkinson RW. Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo Journal For Immunotherapy of Cancer. 2: 128. DOI: 10.1186/2051-1426-2-S3-P128  0.424
2014 Leishman A, Harris O, Ulrichsen JC, Harper J, Popple A, Papaspyridonos M, Williams G, Mullins S, Valge-Archer V, Stewart R, Sainson R, Morrow M, Wilkinson R. Abstract 1651: Profiling immune cells within the tumor microenvironment for optimal model selection for pre-clinical investigations Cancer Research. 74: 1651-1651. DOI: 10.1158/1538-7445.Am2014-1651  0.474
2013 Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 581-9. PMID 23104982 DOI: 10.1096/Fj.12-210377  0.385
2013 Mullins SR, Watkins A, Morrow M, Vallee TL, Robbins P, Stewart R, Wilkinson R. Abstract 4750: Maximising the activity of immune checkpoint blockade through rational combination. Cancer Research. 73: 4750-4750. DOI: 10.1158/1538-7445.Am2013-4750  0.436
2012 Mullins SR, Sameni M, Blum G, Bogyo M, Sloane BF, Moin K. Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biological Chemistry. 393: 1405-16. PMID 23667900 DOI: 10.1515/Hsz-2012-0252  0.596
2012 Sameni M, Mullins SR, Moin K, Sloane BF, Osuala K. Modeling breast cancer progression in 4-D Breast Cancer Metastasis and Drug Resistance: Progress and Prospects. 177-188. DOI: 10.1007/978-1-4614-5647-6_10  0.568
2011 Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. Bmc Cancer. 11: 245. PMID 21668992 DOI: 10.1186/1471-2407-11-245  0.48
2009 Moin K, Schwartz D, Mullins SR, Sloane BF. Microarrays for protease detection in tissues and cells. Methods in Molecular Biology (Clifton, N.J.). 539: 49-57. PMID 19377971 DOI: 10.1007/978-1-60327-003-8_3  0.634
2009 Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. Journal of Medicinal Chemistry. 52: 358-68. PMID 19093877 DOI: 10.1021/Jm801052F  0.494
2009 Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, Olive MB, Rudy D, Sloane BF. Imaging and quantifying the dynamics of tumor-associated proteolysis Clinical and Experimental Metastasis. 26: 299-309. PMID 19082919 DOI: 10.1007/S10585-008-9218-7  0.659
2008 Li Q, Mullins SR, Sloane BF, Mattingly RR. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia (New York, N.Y.). 10: 314-29. PMID 18392133 DOI: 10.1593/Neo.07970  0.589
2007 Narra K, Mullins SR, Lee HO, Strzemkowski-Brun B, Magalong K, Christiansen VJ, McKee PA, Egleston B, Cohen SJ, Weiner LM, Meropol NJ, Cheng JD. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biology & Therapy. 6: 1691-9. PMID 18032930 DOI: 10.4161/Cbt.6.11.4874  0.378
2005 Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, Sloane BF, Bogyo M. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nature Chemical Biology. 1: 203-9. PMID 16408036 DOI: 10.1038/Nchembio728  0.636
Show low-probability matches.